NASDAQ : PRPO
Precipio, Inc. — Company profile
Healthcare · Diagnostics & Research · United States
Last price 19.35 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 34.64M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.
Details
| Name | Precipio, Inc. |
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Employees | 71 |
| Ceo | Ilan Danieli |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US74019L6020 |
| Cusip | 74019L602 |
| Cik | 1043961 |
| Sic | 3826 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Ilan Danieli | Founder, President, Chief Executive Officer and Director |
| Ahmed Zaki Sabet | Chief Operating Officer |
| Dr. Ayman A. Mohamed M.D. | Chief Technology Officer |
| Matthew Gage | Chief Financial Officer |
| Miri Chiko-Radomski | Chief Legal Counsel and People Officer |
Contact
| Address | 4 Science Park, 3rd Floor, New Haven, Connecticut 06511, United States |
| Phone | 203 787 7888 |
| Website | https://www.precipiodx.com |